Project Grant R01HL179905
Award Date 8/15/25
Completion Date 5/31/30
Dollars Obligated $779K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded Temple University a Project Grant titled "INTEGRATE RX: INTEGRATING CLINICAL PHARMACISTS IN HIV CARE TO MITIGATE LAST-MILE CHALLENGES AND REDUCE CARDIOVASCULAR DISEASE BURDEN" under CFDA Program 93.837 Cardiovascular Diseases Research. The $589,297 grant, awarded on Aug 25, 2025, will evaluate the clinical effectiveness and cost-effectiveness of a multi-component pharmacist-led implementation strategy to prevent and manage...
- The National Heart Lung and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, awarded a $3,519,835 Project Grant to the Scripps Research Institute in La Jolla, CA on September 5, 2025. The grant, titled "PLANB2CUREHIV (THE 'PLANB' CONSORTIUM) - PROJECT SUMMARY", aims to accelerate the preclinical development of safe and effective genome-edited B cell-based therapies that could provide long-lasting, broadly neutralizing antibody titers capable of...
- The National Heart, Lung, and Blood Institute (NHLBI), which is part of the National Institutes of Health (NIH), awarded a $688,525 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, San Diego (UCSD). The grant, titled "Blood Pressure Control Advancing Refugee Health Equity (BPCARE): An RCT of Adherence", aims to develop and test a behavioral intervention to improve antihypertensive medication adherence and blood pressure...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $186,408 to the University of Washington to develop robust models that identify patients at high risk for persistent hypoxemic respiratory failure (HRF). The goal is to improve the ability to distinguish patients with persistent HRF early, which is critical for enrolling the highest-risk patients in clinical trials for new HRF...
- This $800,962 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Brigham & Women's Hospital on the molecular mechanisms regulating fibroproliferative pulmonary vasculopathy in early pulmonary arterial hypertension (PAH). The research aims to investigate the role of the c-terminal Src kinase (CSK) and its regulation of Src kinase activation in the context of endothelial dysfunction and fibrosis,...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- The federal Project Grant award of $676,748.00 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to extend neutrophil survival in neutropenia-related pneumonia. The goal is to explore an alternative strategy for treating and preventing neutropenia-related pneumonia by increasing the lifespan of neutrophils in the lungs of neutropenic patients. Specifically, the research will investigate the role and regulation of gasdermin D...
- The University of Washington received a $777,497 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to conduct a hybrid implementation-effectiveness study of a pharmacist-led collaborative care model to improve access to hepatitis C treatment for people who use drugs with housing insecurity. The 5-year project aims to evaluate the reach, adoption, effectiveness, and maintenance of the "Pharmacist, Physician, Patient...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $245,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, with a project period from February 1, 2025 to January 31, 2027, will fund research to validate lipidomic signatures associated with right ventricular and pulmonary vascular dysfunction in pulmonary arterial hypertension (PAH). The project aims to replicate the researchers' preliminary findings on...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $730,070 to the University of Arizona to develop and test a novel class of hybrid polyplex nanoparticles (P22-F1 PBAE/PEI/PEG) that can specifically target and deliver DNA plasmids to lung capillary endothelial cells. The goal is to stimulate lung regeneration and decrease pulmonary hypertension in mouse and rat models of bronchopulmonary dysplasia, a severe...